Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company")  (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to i ...

Core Points - Zealand Pharma held its Annual General Meeting (AGM) on March 26, 2026, in a hybrid format, approving all proposals except for the non-binding advisory vote on the remuneration report [2][3] Financial Performance - The AGM acknowledged the management's report and approved the audited Annual Report for 2025, which showed a net profit after tax of TDKK 6,455,008, to be carried forward to the next financial year [3] Board Elections and Composition - Existing board members were re-elected, and Iris Löw-Friedrich was newly elected to the Board of Directors, while Jeffrey Berkowitz and Bernadette Mary Connaughton did not stand for re-election [4] - The Board of Directors constituted itself with Martin Nicklasson as Chair and Kirsten Aarup Drejer as Vice-Chair [5] Committees - The Audit Committee will include Martin Nicklasson and Leonard Kruimer, with Leonard Kruimer as Chair [5] - The Remuneration Committee will consist of Enrique Conterno Martinelli and Iris Löw-Friedrich, chaired by Martin Nicklasson [5] - The Scientific Committee will include Elaine Sullivan, Enrique Conterno Martinelli, and Iris Löw-Friedrich, chaired by Kirsten Aarup Drejer [6] - The Nomination Committee will consist of Leonard Kruimer and Martin Nicklasson, chaired by Kirsten Aarup Drejer [6] Auditor - PricewaterhouseCoopers (PwC) was re-elected as the auditor for both financial and sustainability reporting [7] Share Buyback Authorization - The Board of Directors was authorized to acquire treasury shares up to 10% of the Company's share capital, with specific conditions regarding financing and pricing [9] Remuneration Report - The non-binding advisory vote on the Remuneration Report did not receive sufficient support for approval [10] Board Fees - The fees for the Board of Directors for the financial year 2026 were approved and remain unchanged from 2025 [11] Company Overview - Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health, leveraging over 25 years of peptide R&D expertise [13] - The company has over 10 drug candidates in clinical development, with two products on the market and three in late-stage development [14]